Emergent Nanotherapeutics in Diabetic Complications

Dr. Awanish Kumar is an Associate Professor of the Department of Biotechnology at the National Institute of Technology, Raipur, Chhattisgarh, India. He has more than 13 years of research experience. He received his PhD in molecular parasitology from the CSIR-Central Drug Research Institute, Lucknow, India, and Jawaharlal Nehru University, Delhi, India, and completed his postdoctoral studies at McGill University, Montreal, Canada. His research interests are infection biology, drug targeting, and drug discovery. Gunjan Adwani is a Ph.D. researcher in the Department of Biotechnology at the National Institute of Technology, Raipur, India. Her research focuses on nanomedicine, advanced drug delivery systems, and diabetes therapeutics, with a primary focus on optimizing insulin delivery strategies. She holds a Bachelor of Science and a Master of Science in Biotechnology from Pt. Ravishankar Shukla University, Raipur. Her current work involves the development of innovative nanocarrier platforms for targeted antidiabetic drug delivery and the formulation of therapeutic interventions to mitigate diabetic comorbidities.

• Part 1 Nanotherapeutics in Diabetic Comorbidities1. Available nano-formulations in diabetes associated comorbidities and their mode of action for translational applications2. Stimuli-responsive nanoplatforms for targeted drug release in diabetic complications: Clinical potential, scalability, and economic feasibility3. Multifunctional nano-formulations: Integrating diagnosis, therapy, and real-time glucose monitoring for diabetic patients with current clinical statusPart 2 Nanotherapeutics for Microvascular Complications related to Diabetes4. Nano-formulations for early-stage diabetic retinopathy: A visionary approach5. Nano-formulations based renal protection: Combating diabetic nephropathy6. Nano-formulations for diabetic neurpathy: Restoring nerve function7. Engineering nanoparticles for improved bloodbrain barrier penetration in diabetic cognitive declinePart 3 Nanotherapeutics for Macrovascular and Metabolic Complications related to Diabetes8. Nano-formulation strategies for cardiovascular disease prevention in diabetes9. Nanomedicine for hypertension in diabetes: Next-generation therapeutics for vascular protection10. Nanotherapeutics for obesity-linked diabetes: A dual-action, effective approach11. Nanotherapeutics for Dyslipidemia, NAFLD, and NASH: A multifaceted approach to metabolic liver disorders in diabetesPart 4 Nanotherapeutics for Wound Healing and Tissue Regeneration in Diabetes12. Nanotherapeutics for diabetic foot ulcers: Smart, clinically relevant wound healing and infection control for cost-effective care13. Nano-formulation strategies for regenerative medicine in diabetes: Toward scalable and economical tissue restoration platformsPart 5 Emerging Trends and Future Perspectives14. Converging nanotechnology and CRISPR-Cas system revolutionize gene editing and diagnostics in diabetes15. 3D and 4D printing of nanostructures: Clinically relevant and scalable technologies for revolutionizing diabetic wound healing16. AI-driven design of nanotherapeutics for the treatment and management of personalized diabetes: Enhancing scalability, cost-effectiveness, and real-time glucose monitoring